All News
Filter News
Found 47 articles
-
Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer’s Disease
1/12/2021
Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced today its lead product has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease.
-
Cognito Therapeutics Appoints Industry Pioneer Brent Vaughan as Chief Executive Officer
12/9/2020
Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of industry veteran Brent Vaughan as Chief Executive Officer.
-
Biotech and pharma companies tap new members of executive leadership teams and boards.
-
Cognito Therapeutics Announces Appointment of Dr. Mihály Hajós as Chief Scientific Officer
6/26/2019
Cognito Therapeutics is a clinical-stage medical device company developing non-invasive neurostimulation therapies for neurodegenerative disorders such as Alzheimer’s disease
-
Report: A vulnerable attack surface exists in healthcare enterprise IT networks
4/24/2019
Vectra research highlights precarious security risks in the healthcare industry due to legacy infrastructures and unmanaged devices
-
Recently published research by MIT neuroscientists indicates that amyloid plaques could be reduced via brain wave stimulation.
-
The Scripps Research Institute Announces New Board Members And Chairman Of The Board
2/21/2017